Immvira Pharma Co. Ltd
Clinical trials sponsored by Immvira Pharma Co. Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental virus injection targets Hard-to-Treat cancers in new trial Results expected Sep 2026 (estimated)
-
Can a Bladder-Directed biologic outsmart Treatment-Resistant bladder cancer?
Disease control Recruiting nowThis phase II trial is testing an experimental biologic called T3011, given directly into the bladder, for people with high-risk non-muscle-invasive bladder cancer that has not responded to BCG therapy or chemotherapy. The study aims to see if this treatment can shrink or elimina…
Phase 2 • Sponsor: ImmVira Pharma Co. Ltd • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Cold war on brain cancer: herpes virus injected into tumors in new trial
Disease control Recruiting nowThis early-stage trial tests a modified herpes virus (C5252) injected directly into the brain tumor cavity of 36 adults with recurrent high-grade glioma who have run out of standard options. The goal is to see if the virus is safe and can help control the disease. Participants wi…
Phase 1/2 • Sponsor: ImmVira Pharma Co. Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Experimental virus injection targets Hard-to-Treat cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called T3011, a modified virus injected directly into tumors, for people with advanced solid cancers like melanoma, lung cancer, or sarcoma. The study will also test T3011 combined with the immunotherapy drug pembrolizumab (Keytruda). …
Phase 1/2 • Sponsor: ImmVira Pharma Co. Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC